Is Natera (NTRA) Fully Valued As Signatera Wins EU IVDR Certification?

Simply Wall St.07-11

Natera (NTRA) is back in focus after securing Class C certification under the European Union’s In Vitro Diagnostic Regulation for its Signatera cancer test, a regulatory milestone that is tied to long...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2650335130?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-07-11 04:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2650335130","market":"sg","top_or_hot":-1,"title":"Is Natera (NTRA) Fully Valued As Signatera Wins EU IVDR Certification?","media":"Simply Wall St.","content":"<div>\n<p>Natera (NTRA) is back in focus after securing Class C certification under the European Union’s In Vitro Diagnostic Regulation for its Signatera cancer test, a regulatory milestone that is tied to long...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntra/natera/news/is-natera-ntra-fully-valued-as-signatera-wins-eu-ivdr-certif\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Natera (NTRA) Fully Valued As Signatera Wins EU IVDR Certification?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Natera (NTRA) Fully Valued As Signatera Wins EU IVDR Certification?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-11 04:44 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntra/natera/news/is-natera-ntra-fully-valued-as-signatera-wins-eu-ivdr-certif><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Natera (NTRA) is back in focus after securing Class C certification under the European Union’s In Vitro Diagnostic Regulation for its Signatera cancer test, a regulatory milestone that is tied to long...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntra/natera/news/is-natera-ntra-fully-valued-as-signatera-wins-eu-ivdr-certif\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2065171402.SGD","symbol_name":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) INC","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntra/natera/news/is-natera-ntra-fully-valued-as-signatera-wins-eu-ivdr-certif","article_id":"2650335130","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntra/natera/news/is-natera-ntra-fully-valued-as-signatera-wins-eu-ivdr-certif","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2650335130","pubTimestamp":1783716249,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Natera (NTRA) is back in focus after securing Class C certification under the European Union’s In Vitro Diagnostic Regulation for its Signatera cancer test, a regulatory milestone that is tied to long term EU market access.\nSee our latest analysis for Natera.\nThe IVDR milestone lands during a strong run for Natera’s stock, with a 30 day share price return of 26.49% and a 90 day share price return of 46.01%. The 1 year total shareholder return of 72.53% and very large 3 year total shareholder...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2065171402.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) INC","LU2264538146.SGD":"Fullerton Lux Funds - Global Absolute Alpha A Acc SGD","LU0053671581.USD":"摩根大通美国小盘成长股 A(dist)","LU2065169927.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) ACC","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","LU0012050646.USD":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" (USD) INC AV","HELX":"Franklin Genomic Advancements ETF","LU2065731478.USD":"ALLSPRING (LUX) WORLDWIDE FUND - SMALL CAP INNOVA \"I\" (USD) ACC","LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","GNOM":"Global X Genomics & Biotechnology ETF","LU1988902786.USD":"FULLERTON LUX FUNDS GLOBAL ABSOLUTE ALPHA \"I\" (USD) ACC","LU0106261612.USD":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" ACC","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","BK4156":"煤与消费用燃料","LU0345770308.USD":"NINETY ONE GSF GLOBAL STRATEGIC EQUITY \"A\" (USD) ACC","LU0345770993.USD":"NINETY ONE GSF GLOBAL STRATEGIC EQUITY \"A\" (USD) INC","LU0963586101.USD":"ALLIANZ GLOBAL SMALL CAP EQUITY \"AT\" ACC","LU2065170008.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) INC","LU2065171311.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) ACC","BK4139":"生物科技","NTRA":"Natera, Inc."},"translate_title":"随着 Signatera 获得欧盟 IVDR 认证，Natera (NTRA) 是否得到充分重视？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DCF":1,"NTRA":1.5,"GNOM":0.6,"HELX":0.6},"content_text":"Natera (NTRA) is back in focus after securing Class C certification under the European Union’s In Vitro Diagnostic Regulation for its Signatera cancer test, a regulatory milestone that is tied to long term EU market access. See our latest analysis for Natera. The IVDR milestone lands during a strong run for Natera’s stock, with a 30 day share price return of 26.49% and a 90 day share price return of 46.01%. The 1 year total shareholder return of 72.53% and very large 3 year total shareholder return signal sustained momentum around its cancer testing platform. If this cancer testing story has your attention, it could be a good moment to look at other potential healthcare AI opportunities using our curated 40 healthcare AI stocks After such a rapid move in Natera, the trade-off is clear: pay up for the momentum, or wait and risk watching the stock run without you. How do today's fundamentals stack up against that choice? AdvertisementMost Popular Narrative: 8.4% Overvalued Natera’s most followed narrative pegs fair value at $260.05, modestly below the last close of $281.85, raising clear questions about what is built into the story.  Investment in new product launches (e.g., Fetal Focus NIPT, Signatera Genome, AI-based biomarkers) and a robust R&D pipeline positions Natera to capture growth from long-term trends in personalized medicine and early detection, underpinning future revenue expansion.  Read the complete narrative. Want to see what is behind that premium tag on Natera? The narrative leans on strong revenue compounding, higher margins, and a punchy earnings profile that drives the fair value call. Result: Fair Value of $260.05 (OVERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, Natera’s story could look very different if clinical trials or reimbursement decisions disappoint, or if rising R&D and commercial spending delays a clear path to profitability. Find out about the key risks to this Natera narrative. Another View: SWS DCF Points to a Very Different Natera Valuation While the most popular Natera narrative flags the stock as 8.4% overvalued against a $260.05 fair value, the SWS DCF model points in the opposite direction, suggesting the shares trade about 49% below an estimated future cash flow value of $552.95. Two models, two very different answers. Which one better matches how you think cash flows and risk will actually play out for this business? Look into how the SWS DCF model arrives at its fair value. NTRA Discounted Cash Flow as at Jul 2026Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Natera for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 44 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity. Next Steps Interested in how balanced the Natera story really is right now? Take a closer look at the full picture and consider the 2 key rewards and 1 important warning sign. Looking for more investment ideas beyond Natera? If Natera has sharpened your interest in what is possible, do not stop at one stock when a few smart filters could reshape your entire watchlist.  Target quality at a discount by scanning for companies that score well on fundamentals yet trade at appealing prices using the 44 high quality undervalued stocks. Lock in reliability by focusing on companies with robust finances through the solid balance sheet and fundamentals stocks screener (47 results). Spot tomorrow's potential standouts before the crowd by running the screener containing 19 high quality undiscovered gems.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Natera might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2650335130","isCrawlerRequest":true}